Patent intelligence · US
US 12162949
CD38 antibody
CD38 antibody
Patent details — US 12162949
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2024
- Expiration
- Dec 5, 2044
- Applicant
- BLACK BELT THERAPEUTICS LIMITED
- Claims
- 12
- CPC classes
- A61K, A61K2039/507, A61K39/39558, A61P
Quick answer
US 12162949 (CD38 antibody) is held by BLACK BELT THERAPEUTICS LIMITED. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BLACK BELT THERAPEUTICS LIMITED
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/507, A61K39/39558, A61P, A61P35/00
More from BLACK BELT THERAPEUTICS LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12325699
Antibacterial compounds
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 12162949?
US 12162949 (CD38 antibody) is held by BLACK BELT THERAPEUTICS LIMITED. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12162949?
BLACK BELT THERAPEUTICS LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 12162949 expire?
Our index shows an expiration date of Dec 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.